This trial is evaluating whether MT-0169 will improve 16 primary outcomes and 37 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Cycles 1 and 2, Day 1: pre-dose, and at multiple time points (up to 168 hours) post-dose (each cycle is 28 days).
This trial requires 144 total participants across 12 different treatment groups
This trial involves 12 different treatments. MT-0169 is the primary treatment being studied. Participants will be divided into 12 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"In most cases, multiple myeloma arises from a single monoclonal clonal cell of B cell phenotype and origin, a precursor-differentiated B cell (plasmablasts or plasma cells). The exact cell-origin or pathogenetically abnormal circumstances are not known. The risk factors for developing multiple myeloma (including exposure to ionizing radiation, chronic inflammation and aging) are well established." - Anonymous Online Contributor
"Common treatment options for multiple myeloma include the administration of bortezomib, lenalidomide, dexamethasone and high dose melphalan. Another common treatment is the administration of a proteasome inhibitor such as carfilzomib or ixabepilone. Other treatments are radiotherapy or transplantation. There is no cure for multiple myeloma, so treatment is focused on controlling symptoms and prolonging survival." - Anonymous Online Contributor
"Many people in the USA get multiple myeloma, but most people do not realize it is a serious illness that can have serious long-term effects on people's health. This report indicates that there are many people getting multiple myeloma." - Anonymous Online Contributor
"Patients with multiple myeloma can achieve a 20- to 30-year survival, which equals or exceeds the 20- to 25-year survival for patients with normal plasma protein levels. However, most patients with multiple myeloma may become symptomatic even on the normal level." - Anonymous Online Contributor
"Myeloma often first presents with nonspecific symptoms such as fatigue/loss of appetite. Other signs may include anemia and weight loss, which may precede pain and a raised level of serum protein in the blood. Bone lesions in advanced disease often cause back pain, which is the initial presenting symptom in about half of cases. A change in bowel habit such as bleeding in the stool or vomiting blood is another feature of [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) in the non-plasma cell stage of disease." - Anonymous Online Contributor
"There is a large amount of information available on the internet pertaining to multiple myeloma from health-care providers, medical research groups, patient support groups, and on the internet. Results from a recent paper of the current study showed that general information was the largest source of information about multiple myeloma." - Anonymous Online Contributor
"The most common side-effects experienced by the women in our study were transient, mild, and transient nausea, nausea and fatigue, and occasional hair loss and dry scalp at the nape, but these were minimal. Patients should not experience more than a common side-effect and be aware of this during discussions on consent and consent forms and documentation. Patients should be cautious about use in those with a history of allergies. The other side effects observed, such as dizziness, chest tightness, chest pains, breathlessness and difficulty breathing, were transient, and did not seem more than a mild inconvenience. Patients should not experience other side effects which they have experienced before, such as rash, swelling, headache and/or diarrhoea." - Anonymous Online Contributor
"In Japan, most multiple myeloma patients are treated as one group with chemotherapy and radiotherapy. mt-0169 is used in combination with any other treatments and the median time to progression is 4.9 months." - Anonymous Online Contributor
"Itraconazole, itrudim, and amiodarone induce hepatotoxicity, and the cumulative use of these three drugs is associated with rhabdomyolysis in multiple myeloma patients. The common use of itraconazole does not result in any side effects." - Anonymous Online Contributor
"More than 30% of patients with MM will not die of the disease within the 5 yr following diagnosis. It is unclear whether disease or treatment related causes were at play. Because more intensive and earlier therapy has not led to a survival benefit for patients with MM in more recent years, it may be necessary to rethink the role of chemotherapy in the treatment of patients with MM." - Anonymous Online Contributor
"Nearly 80% of patients with multiple myeloma get the disease under the age of 50 years. However, there have not been any studies to determine what percentage of patients under the age of 40 get multiple myeloma. However, a study conducted by the American Cancer Society suggests that 1 in 18,900 people (0.05%) get multiple myeloma at age 20-39 years. When calculating the average age of someone develops multiple myeloma, you must take the age of everyone that goes to that hospital in the past year. So the average age someone develops the disease is 2 years after getting admitted to a hospital for any reason, not from bone marrow cancer." - Anonymous Online Contributor
"In this large multiethnic [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) family-based study, we do not observe an increased risk of familial multiple myeloma or an increased risk of new occurrence of myeloma with no family history of multiple myeloma. In the future, confirmation of these results will be strengthened by combining these results with those from other studies on familial myeloma." - Anonymous Online Contributor